Prognostic Role of TMED3 in Clear Cell Renal Cell Carcinoma: A Retrospective Multi-Cohort Analysis
Prognostic Role of TMED3 in Clear Cell Renal Cell Carcinoma: A Retrospective Multi-Cohort Analysis
复制标题
DOI：
10.3389/fgene.2019.00355
复制
发表时间：
2019-04-17
影响因子：
3.7
通讯作者：
Lee, Dongjun
中科院分区：
文献类型：
--
作者：
Ha, Mihyang;Moon, Hwan;Lee, Dongjun
跨膜 p24 运输蛋白 3 (TMED3) 是结肠癌和肝细胞癌的转移抑制因子。然而，其在透明细胞肾细胞癌（ccRCC）进展中的功能尚不清楚。在这里，我们报告 TMED3 可能成为 ccRCC 的新预后标志物。患者数据是从癌症基因组图谱 (TCGA) 和国际癌症基因组联盟 (ICGC) 的队列中提取的。在 TOGA 和 ICGC 队列中的低分期（I 和 II 期）和高分期（III 和 IV 期）患者以及 TOGA 队列中的低分期（I 和 II 级）和高分期（III 和 IV 级）患者之间观察到 TMED3 的差异表达。此外，我们使用 Kaplan-Meier 生存分析、多变量分析、Uno C 指数的时间依赖性曲线下面积 (AUC) 以及 5 年受试者操作特征的 AUC 来评估 TMED3 表达作为预后基因。 Kaplan-Meier 分析显示，TMED3 过度表达与 ccRCC 患者的不良预后相关。对 C 指数和接受者操作特征曲线下面积的分析进一步支持了这一点。多变量分析证实了 TMED3 表达水平的预后意义（TOGA 和 ICGC 的 P 值分别为 0.005 和 0.006）。总而言之，这些发现表明 TMED3 是 ccRCC 的潜在预后因素。
Transmembrane p24 trafficking protein 3 (TMED3) is a metastatic suppressor in colon cancer and hepatocellular carcinoma. However, its function in the progression of clear cell renal cell carcinoma (ccRCC) is unknown. Here, we report that TMED3 could be a new prognostic marker for ccRCC. Patient data were extracted from cohorts in the Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC). Differential expression of TMED3 was observed between the low stage (Stage I and II) and high stage (Stage III and IV) patients in the TOGA and ICGC cohorts and between the low grade (Grade I and II) and high grade (Grade III and IV) patients in the TOGA cohort. Further, we evaluated TMED3 expression as a prognostic gene using Kaplan-Meier survival analysis, multivariate analysis, the time-dependent area under the curve (AUC) of Uno's C-index, and the AUC of the receiver operating characteristics at 5 years. The Kaplan-Meier analysis revealed that TMED3 overexpression was associated with poor prognosis for ccRCC patients. Analysis of the C-indices and area under the receiver operating characteristic curve further supported this. Multivariate analysis confirmed the prognostic significance of TMED3 expression levels (P = 0.005 and 0.006 for TOGA and ICGC, respectively). Taken together, these findings demonstrate that TMED3 is a potential prognostic factor for ccRCC.